iRhythm/$IRTC
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About iRhythm
iRhythm Technologies Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.
Ticker
$IRTC
Sector
Health
Primary listing
Employees
2,000
Headquarters
Website
iRhythm Metrics
BasicAdvanced
$5.2B
-
-$2.93
1.41
-
Price and volume
Market cap
$5.2B
Beta
1.41
52-week high
$168.32
52-week low
$55.92
Average daily volume
502K
Financial strength
Current ratio
5.022
Quick ratio
4.748
Long term debt to equity
693.019
Total debt to equity
708.802
Interest coverage (TTM)
-4.03%
Profitability
EBITDA (TTM)
-47.434
Gross margin (TTM)
69.78%
Net profit margin (TTM)
-14.06%
Operating margin (TTM)
-8.09%
Effective tax rate (TTM)
-0.90%
Revenue per employee (TTM)
$330,000
Management effectiveness
Return on assets (TTM)
-3.53%
Return on equity (TTM)
-91.13%
Valuation
Price to revenue (TTM)
7.707
Price to book
49.73
Price to tangible book (TTM)
50.14
Price to free cash flow (TTM)
393.23
Free cash flow yield (TTM)
0.25%
Free cash flow per share (TTM)
0.408
Growth
Revenue change (TTM)
22.37%
Earnings per share change (TTM)
-31.26%
3-year revenue growth (CAGR)
22.03%
3-year earnings per share growth (CAGR)
-12.81%
What the Analysts think about iRhythm
Analyst ratings (Buy, Hold, Sell) for iRhythm stock.
iRhythm Financial Performance
Revenues and expenses
iRhythm Earnings Performance
Company profitability
iRhythm News
AllArticlesVideos
IRHYTHM INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of iRhythm Technologies, Inc. - IRTC
Business Wire·3 weeks ago
IRHYTHM INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of iRhythm Technologies, Inc. - IRTC
Business Wire·2 months ago
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against iRhythm Technologies, Inc. (IRTC) and Encourages Investors to Learn More About the Investigation
Accesswire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for iRhythm stock?
iRhythm (IRTC) has a market cap of $5.2B as of August 12, 2025.
What is the P/E ratio for iRhythm stock?
The price to earnings (P/E) ratio for iRhythm (IRTC) stock is 0 as of August 12, 2025.
Does iRhythm stock pay dividends?
No, iRhythm (IRTC) stock does not pay dividends to its shareholders as of August 12, 2025.
When is the next iRhythm dividend payment date?
iRhythm (IRTC) stock does not pay dividends to its shareholders.
What is the beta indicator for iRhythm?
iRhythm (IRTC) has a beta rating of 1.41. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.